TY - JOUR
T1 - Electrochemical studies of a series of antimetastatic mono- and di-ruthenium complexes [Na][trans-RuIIICl4(DMSO)(L)] and [Na]2[{trans-RuIIICl4(DMSO)}2(μ-L)] (L = N-donor heterocyclic bridging ligand)
AU - Ravera, Mauro
AU - Gabano, Elisabetta
AU - Baracco, Sara
AU - Sardi, Manuele
AU - Osella, Domenico
N1 - Funding Information:
This research was carried out within the framework of the European Cooperation COST D39 (Metallo-Drug Design and Action) and was supported by Associazione ATF (Ambiente Territorio e Formazione, Alessandria, Italy) and Consorzio CIRCMSB (Chimica dei Metalli nei Sistemi Biologici, Bari, Italy). We are indebted to Dr. Laura McLean for useful linguistic suggestions.
PY - 2008/6/27
Y1 - 2008/6/27
N2 - A study of the electrochemical behavior of a series of antimetastatic mono- and di-ruthenium complexes, namely [Na][trans-RuIIICl4(DMSO)(L)] and [Na]2[{trans-RuIIICl4(DMSO)}2(μ-L)], L = pyrazine (pyz), pyrimidine (pym), 4,4′-bipyridine (bipy), and 1,2-bis-(4-pyridyl)ethylene (etbipy), is reported. The results obtained show that in all dimeric Ru(III) complexes linked by heterocyclic non-chelating N-donor bridges, the two redox centers behave independently (with no remarkable electrochemical interaction), thus conferring no advantage in the likely hypothesis they act as pro-drugs (activation by reduction). Moreover, electrochemical evaluation of interaction between albumin and the title complexes confirms that this protein can act as the vehicle for drugs of this type in blood.
AB - A study of the electrochemical behavior of a series of antimetastatic mono- and di-ruthenium complexes, namely [Na][trans-RuIIICl4(DMSO)(L)] and [Na]2[{trans-RuIIICl4(DMSO)}2(μ-L)], L = pyrazine (pyz), pyrimidine (pym), 4,4′-bipyridine (bipy), and 1,2-bis-(4-pyridyl)ethylene (etbipy), is reported. The results obtained show that in all dimeric Ru(III) complexes linked by heterocyclic non-chelating N-donor bridges, the two redox centers behave independently (with no remarkable electrochemical interaction), thus conferring no advantage in the likely hypothesis they act as pro-drugs (activation by reduction). Moreover, electrochemical evaluation of interaction between albumin and the title complexes confirms that this protein can act as the vehicle for drugs of this type in blood.
KW - Albumin
KW - Antimetastatic compounds
KW - Cyclic voltammetry
KW - Electrochemistry
KW - Protein-metal interaction
KW - Ruthenium complexes
UR - https://www.scopus.com/pages/publications/44649203891
U2 - 10.1016/j.ica.2008.02.031
DO - 10.1016/j.ica.2008.02.031
M3 - Article
SN - 0020-1693
VL - 361
SP - 2879
EP - 2886
JO - Inorganica Chimica Acta
JF - Inorganica Chimica Acta
IS - 9-10
ER -